查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1481293

骨髓增生性疾病药物/治疗市场规模 - 依疾病类型（Ph+ CML、Ph- MPN [真性红血球增多症、原发性血小板增多症、骨髓纤维化]）、药物类别（酪胺酸激酶、JAK）、给药途径、最终用途和预测，2024 年 - 2032

Myeloproliferative Disorders Drugs/Treatment Market Size - By Disorder Type (Ph+ CML, Ph- MPN [Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis]), Drug Class (Tyrosine Kinase, JAK), Route of Administration, End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于真性红血球增多症、原发性血小板增多症和骨髓纤维化等骨髓增生性疾病的盛行率不断增加，骨髓增生性疾病药物/治疗市场预计 2024 年至 2032 年复合年增长率为 3.2%。根据 AACR（美国癌症研究协会）的数据，美国估计有 13,000 人患有骨髓纤维化。因此，对有效药物和治疗方法来控制症状、改善生活品质和延长患者生存期的需求不断增长。此外，医学研究和药物开发的进步导致针对骨髓增殖性疾病特定分子途径的新疗法的发现。

随着全球人口老化，这些疾病的盛行率预计将上升，进一步推动对药物和治疗的需求。此外，医疗保健专业人员和患者对早期诊断和及时干预的意识正在增强。对及时诊断的高度重视，因为它允许启动适当的治疗来帮助管理症状、预防疾病进展和改善患者的治疗结果，这将有利于市场的成长。

骨髓增生性疾病药物/治疗产业分为疾病类型、药物类别、给药途径、最终用途和地区。

根据给药途径，口腔领域的市场价值预计在2024 年至2032 年期间以3.1% 的复合年增长率增长，因为它们为患者提供了便利和灵活性，使他们能够在家中进行治疗，而无需频繁去诊所就诊。这增强了患者的便利性，从而提高了治疗依从性并提高了生活品质。此外，药物研究的进步导致针对骨髓增生性疾病特定分子途径的口服药物的开发，以提供更有效和有针对性的治疗选择。

就最终用途而言，到2032 年，专科诊所领域的骨髓增殖性疾病药物/治疗市场将实现3.3% 的增长率。护理所推动的。这些诊所提供量身定制的治疗计划、密切监测和先进疗法，以确保疾病的最佳管理。此外，专科诊所通常充当转诊中心，吸引来自广泛地理区域寻求专业护理的患者。此外，专科诊所和製药公司之间为促进临床试验和创新疗法开发而进行的合作正在进一步推动市场成长。

由于医学研究和药物开发的进步，欧洲骨髓增生性疾病药物治疗市场规模到 2032 年可能会以 3.3% 的复合年增长率大幅扩张，特别是在德国和英国等拥有健全医疗保健系统的国家。专注于血液疾病的学术中心将促进临床医生和研究人员之间的合作，从而开发客製化疗法。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球骨髓增生性疾病发生率不断上升
      • 加大新药研发力度
      • 标靶治疗不断进步
      • 老年人口增加
    • 产业陷阱与挑战
      • 治疗选择有限
      • 治疗费用高
      • 与药物相关的不良反应
  • 成长潜力分析
  • 管道分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析，
  • 竞争定位矩阵
  • 战略仪錶板

第 5 章：市场估计与预测：按疾病类型，2018-2032

  • 主要趋势
  • 费城染色体阳性 (Ph+) CML
  • 费城染色体阴性 (Ph-) MPN
    • 真性红血球增多症
    • 原发性血小板增多症
    • 骨髓纤维化
  • 其他疾病类型

第 6 章：市场估计与预测：按药物类别，2018-2032 年

  • 主要趋势
  • 酪胺酸激酶抑制剂
  • Janus激酶抑制剂
  • 羟基脲
  • 其他药物类别

第 7 章：市场估计与预测：按管理途径，2018-2032 年

  • 主要趋势
  • 口服
  • 可注射

第 8 章：市场估计与预测：按最终用途，2018-2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 10 章：公司简介

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • GL Pharma GmbH
  • Incyte Corporation
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • MorphoSys AG
  • Mylan N.V. (Viatris)
  • Novartis Pharmaceuticals Corporation (Novartis AG)
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: 8372

Myeloproliferative disorders drugs/treatment market is estimated to register 3.2% CAGR between 2024 and 2032, owing to the increasing prevalence of myeloproliferative disorders, such as polycythemia vera, essential thrombocythemia, and myelofibrosis. As per AACR (American Association for Cancer Research), an estimated 13,000 people were living with myelofibrosis in the U.S. These disorders are characterized by the abnormal production of blood cells in the bone marrow, leading to various complications. Consequently, there is a growing demand for effective drugs and treatments to manage symptoms, improve quality of life, and prolong survival among patients. Additionally, advancements in medical research and drug development have led to the discovery of novel therapies targeting specific molecular pathways involved in myeloproliferative disorders.

With aging population worldwide, the prevalence of these conditions is expected to rise, further driving the demand for drugs and treatments. Moreover, the awareness among healthcare professionals and patients about early diagnosis and prompt intervention is increasing. The strong focus on timely diagnosis as it allows the initiation of appropriate treatments to help manage symptoms, prevent disease progression, and improve patient outcomes will favor the market growth.

The myeloproliferative disorders drugs/treatment industry is classified into disorder type, drug class, route of administration, end-use and region.

Based on route of administration, the market value from the oral segment is slated to grow at 3.1% CAGR during 2024-2032, as they offer convenience and flexibility for patients, allowing them to administer treatments at home without the need for frequent clinic visits. This enhanced patient convenience leads to better treatment adherence and improved quality of life. Additionally, advancements in pharmaceutical research have resulted in the development of oral drugs targeting specific molecular pathways involved in myeloproliferative disorders for offering more effective and targeted treatment options.

In terms of end-use, the myeloproliferative disorders drugs/treatment market from the specialty clinics segment will record 3.3% growth rate through 2032. This is driven by their specialized expertise and comprehensive care in managing complex hematologic conditions like myeloproliferative disorders. These clinics provide tailored treatment plans, close monitoring, and access to advanced therapies for ensuring optimal management of the disease. Additionally, specialty clinics often serve as referral centers, attracting patients seeking specialized care from a wide geographic area. Moreover, collaborations between specialty clinics and pharmaceutical companies for facilitating clinical trials and the development of innovative therapies are further driving the market growth.

Europe myeloproliferative disorders drug treatment market size may expand substantially at 3.3% CAGR up to 2032, attributed to the advancements in medical research and drug development, particularly in countries with robust healthcare systems like Germany and the U.K. Furthermore, the presence of specialized healthcare facilities and academic centers focusing on hematologic diseases in Europe will foster collaboration between clinicians and researchers, leading to the development of tailored therapies.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 Data collection
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of myeloproliferative diseases globally
      • 3.2.1.2 Increasing R&D efforts to develop new drugs
      • 3.2.1.3 Growing advancement in targeted therapies
      • 3.2.1.4 Increasing geriatric population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Limited treatment options
      • 3.2.2.2 High cost of treatment
      • 3.2.2.3 Adverse effects associated with the drugs
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players,
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disorder Type, 2018-2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Philadelphia chromosome-positive (Ph+) CML
  • 5.3 Philadelphia chromosome-negative (Ph-) MPNs
    • 5.3.1 Polycythemia vera
    • 5.3.2 Essential thrombocythemia
    • 5.3.3 Myelofibrosis
  • 5.4 Other disorder types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Tyrosine kinase inhibitors
  • 6.3 Janus kinase inhibitors
  • 6.4 Hydroxyurea
  • 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Bristol-Myers Squibb Company
  • 10.3 Eli Lilly and Company
  • 10.4 GlaxoSmithKline plc (GSK)
  • 10.5 GL Pharma GmbH
  • 10.6 Incyte Corporation
  • 10.7 Janssen Biotech, Inc. (Johnson & Johnson)
  • 10.8 MorphoSys AG
  • 10.9 Mylan N.V. (Viatris)
  • 10.10 Novartis Pharmaceuticals Corporation (Novartis AG)
  • 10.11 Takeda Pharmaceutical Company Limited
  • 10.12 Teva Pharmaceutical Industries Ltd.